Fig. 1 · Structure

Documents & Downloads

Bexarotene (LGD1069)

Cat. No. A11094 CAS 153559-49-0

Retinoid X Receptor Ligand

Bexarotene is a highly selective retinoid X receptor (RXR) agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
RXR

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 26.5 μM Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay [PMID: 32422522]
A-375 IC50 28.4 μM Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay [PMID: 32422522]
BT-549 EC50 > 56 μM Cytotoxicity against human BT549 cells assessed as reduction in cell viability by MTT assay [PMID: 29287960]
Caco-2 EC50 52 nM Agonist activity at human recombinant Gal4-tagged RXRalpha expressed in human Caco-2 cells assessed as receptor homodimerization after 24 hrs by mammalian two hybrid assay [PMID: 19791803]
COS-1 EC50 20 nM Agonist activity at RXRalpha (unknown origin) expressed in COS1 cells incubated for 18 hrs by luciferase reporter gene assay [PMID: 25815156]
COS-1 EC50 20 nM Agonist activity at RXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay [PMID: 24900241]
CV-1 EC50 0.04 μM Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay [PMID: 19216008]
DU-145 IC50 61.6 μM Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 23707260]
FaDu IC50 29.8 μM Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay [PMID: 32422522]
HEK293 EC50 149 nM Transactivation of human RXRalpha transfected in human 293 cells after 48 hrs by dual-luciferase reporter gene assay [PMID: 23707260]
HEK293 EC50 40 nM Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay [PMID: 24801499]
HEK-293T EC50 0.196 μM Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay [PMID: 28169169]
HEK-293T EC50 0.434 μM Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay [PMID: 28169169]
Hep 3B2 IC50 191.8 μM Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 23707260]
HepG2 IC50 20 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay [PMID: 33793232]
HGC-27 IC50 32.7 μM Cytotoxicity against human HGC27 cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 23707260]
HT-29 IC50 > 30 μM Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay [PMID: 32422522]
KB IC50 46.3 μM Cytotoxicity against bexarotene-resistant human KB cells assessed as growth inhibition after 48 hrs by MTT assay [PMID: 23707260]
KB IC50 8.8 μM Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay [PMID: 23707260]

19 records · Scroll to view more

Bexarotene (LGD1069) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Bexarotene (LGD1069) from 3 published references. In vitro models include human neuroblastoma cells. In vivo models include 6-week-old athymic nude mice.

Bexarotene (LGD1069) In Vitro Studies

In human neuroblastoma cells, Aβ42 aggregation samples prepared with Bexarotene produced lower toxicity at early incubation times than samples prepared without it, but toxicity became similar after 7 hours. In a separate ThT fluorescence assay, Bexarotene significantly delayed Aβ42 aggregation compared with its absence. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Toxicity of amyloid aggregation samples in human neuroblastoma cells

Cell-based study · human neuroblastoma cells (SH-SY5Y) [1]

In the absence of bexarotene, the species formed after incubation for 0.3 hours and 4 hours exhibited a level of toxicity 65 ± 5% higher than that in the presence of bexarotene. However, for the samples incubated for 7 hours, the level of toxicity generated in the presence of bexarotene increased to a value similar to that observed in its absence whereas the toxicity of Aβ alone decreased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
activity of caspase-3caspase-3 activity a level of toxicity 65 ± 5% higher than that in the presence of bexarotene[1]

Literature-Reported Treatment Conditions

Treatment concentration
20-fold excess (that is, 10 μM)
Exposure duration
after incubation for 0.3 hours (Fig. 5D) and 4 hours (Fig. 5E); an additional 24 hours
Method
Aliquots of Aβ42 solutions were removed at different time points during the lag phase of the aggregation reaction in the absence and presence of bexarotene and incubated with SH-SY5Y neuroblastoma cells
Vehicle
1% DMSO final concentration
Co-treatment
Other interventions in this design: Aβ42 0.5 μM. Compound effect isolated by the comparison: Aβ42 in the absence and in the presence of bexarotene.
Methods and source locations

Compound reported in the paper: Bexarotene

Evidence for Bexarotene as the phosphate form reported in the paper, not the free base/neutral form supplied as A11094; no salt equivalence, dose conversion or lot validation.

RESULTS > Targeting primary nucleation delays the formation of toxic species of Aβ42 (S76, S79, S81, S82); MATERIALS AND METHODS > Caspase-3 cytotoxicity assay (S174, S178, S183, S184, S189, S194)

activity of caspase-3: activity of caspase-3; comparator: Aβ either alone — RESULTS > Targeting primary nucleation delays the formation of toxic species of Aβ42 (S81, S82); MATERIALS AND METHODS > Caspase-3 cytotoxicity assay (S174)

Delayed amyloid aggregation in a fluorescence assay

Cell-based study · 2 μM Aβ42 [2]

In an assay using 2 μM Aβ42, Bexarotene at a 3:1 concentration ratio significantly delayed aggregation, as measured by ThT fluorescence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ThT fluorescenceReported result Bexarotene delayed the aggregation of Aβ42 significantly, by inhibiting both primary and surface-catalysed secondary nucleation[2]

Literature-Reported Treatment Conditions

Treatment concentration
3:1 concentration ratio
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Bexarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Bexarotene inhibits Aβ42 aggregation (S9); Methods > Sample preparation for kinetic experiments (S69); Methods > Kinetic assays (S73, S74); Fig. 1 legend (S121)

ThT fluorescence: ThT fluorescence; comparator: absence — Results > Bexarotene inhibits Aβ42 aggregation (S9); Methods > Kinetic assays (S73, S74)

Bexarotene (LGD1069) In Vivo Studies

In athymic nude mice, oral Bexarotene reduced lung tumour formation by more than 50% compared with vehicle control in both tumour models when treatment began 1 day after tumour injection. In a C. elegans model of Aβ42-mediated dysfunction, 10 μM Bexarotene supplied at the L1 and L4 larval stages completely maintained motility, reaching the level observed in control worms; the compound comparison used plates seeded only with 1% DMSO. [3,1]

Reduced lung tumour formation in mice

Animal study · 6-week-old athymic nude mice [3]

Athymic nude mice received Bexarotene orally at 100 mg kg−1 daily for 6 weeks. Lung tumour formation was reduced by more than 50% compared with vehicle control in both tumour models when treatment began 1 day after tumour injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
numbers of tumour nodules in the lunglung tumour formation more than 50%[3]

Conditions shared by the study groups

Route
orally
Treatment course
daily for 6 weeks
Vehicle
an aqueous solution containing 10% (v v−1) polyethylene glycol (Mr 400)/Tween 80 (99.5 : 0.5) and 90% of 1% (w v−1) carboxymethylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bexarotene 100 mg kg−1vehicle controlreduced more than 50% lung tumour formation compared to the vehicle control in both tumour models when treatment began 1 day after tumour injection[3]
Bexarotene 100 mg kg−1
Model: 6-week-old athymic nude mice
Methods and source locations

Compound reported in the paper: Bexarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > In vivo experimental metastasis studies (S8, S9, S15); RESULTS > Bexarotene inhibits the development of angiogenesis and metastasis in vivo (S76); Figure 1 legend (S108)

numbers of tumour nodules in the lung: numbers of tumour nodules in the lung; comparator: vehicle control — RESULTS > Bexarotene inhibits the development of angiogenesis and metastasis in vivo (S76); Figure 1 legend (S108)

Bexarotene 100 mg kg−1 · MATERIALS AND METHODS > In vivo experimental metastasis studies (S15); RESULTS > Bexarotene inhibits the development of angiogenesis and metastasis in vivo (S76)

Maintained motility in an amyloid worm model

Animal study · C. elegans model of Aβ42-mediated dysfunction, denoted GMC101; Two hundred animals were counted per experiment unless stated otherwise [1]

In a C. elegans model of Aβ42-mediated dysfunction, Bexarotene was supplied through media at 10 μM at the L1 and L4 larval stages. Against the comparison with plates seeded only with 1% DMSO, motility was completely maintained, reaching the level observed in control worms.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
frequency of body bendsReported result the motility of the Aβ worms was maintained completely upon addition of 10 μM bexarotene in two bursts at the L1 and L4 larval stages, that is, reached the level observed in the control worms[1]

Conditions shared by the study groups

Route
transferred onto media with compound
Treatment course
in two bursts at the L1 and L4 larval stages
Vehicle
1% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bexarotene 10 μMplates seeded only with 1% DMSOthe motility of the Aβ worms was maintained completely upon addition of 10 μM bexarotene in two bursts at the L1 and L4 larval stages, that is, reached the level observed in the control worms[1]
Bexarotene 10 μM
Model: C. elegans model of Aβ42-mediated dysfunction, denoted GMC101; Two hundred animals were counted per experiment unless stated otherwise
Methods and source locations

Compound reported in the paper: Bexarotene

Evidence for Bexarotene as the phosphate form reported in the paper, not the free base/neutral form supplied as A11094; no salt equivalence, dose conversion or lot validation.

RESULTS > Bexarotene rescues Aβ42-mediated dysfunction in C. elegans models (S84, S86, S90); MATERIALS AND METHODS > Preparation of samples for kinetic experiments (S127); MATERIALS AND METHODS > Dot-blot assay (S152); MATERIALS AND METHODS > NMR experiments (S158); MATERIALS AND METHODS > C. elegans experiments (S199, S202, S209, S211, S212); MATERIALS AND METHODS > C. elegans motility assay (S215)

frequency of body bends: frequency of body bends; comparator: plates seeded only with 1% DMSO — RESULTS > Bexarotene rescues Aβ42-mediated dysfunction in C. elegans models (S86, S90)

Bexarotene 10 μM · RESULTS > Bexarotene rescues Aβ42-mediated dysfunction in C. elegans models (S90); MATERIALS AND METHODS > C. elegans experiments (S209)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 153559-49-0
Applications Retinoid X Receptor Ligand
Formula C24H28O2
Molecular Weight 348.5
Synonyms LGD 1069; SR 11247; Ro 26-4455; Targretin; LG 100069
SMILES
CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 7 mg/mL (20.11 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bexarotene (LGD1069) Research References

  1. [1] Habchi J, Arosio P, Perni M, et al. An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease. Sci Adv (2016). PMID: 26933687 DOI: 10.1126/sciadv.1501244 Source material
  2. [2] Ruggeri FS, Habchi J, Chia S, et al. Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single Aβ42 oligomers. Nat Commun (2021). PMID: 33514697 DOI: 10.1038/s41467-020-20782-0 Source material
  3. [3] Yen WC, Prudente RY, Corpuz MR, et al. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer (2006). PMID: 16495926 DOI: 10.1038/sj.bjc.6602995 Source material

Added to your cart

View Cart Checkout
Loading...